| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Hidden intestinal angiosarcoma behind anemia during tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tala Najdi, Samah Seif, Diana Khoury, Antony Kahwagi, Perla Wehbe, Rita Karam, Layal El Halabi, Rita Slim, Ghassan Chakhtoura, Viviane Trak and Roland Eid |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Tala Najdi, MD, Department of Hematoogy-Oncology, Hotel-Dieu de France University Hospital., Faculty of Medicine, Saint Joseph University, Beirut, Lebanon., Achrafieh, Beirut 166830, Lebanon. tala.najdi@net.usj.edu.lb |
| Key Words |
Intestinal angiosarcoma; Epithelioid angiosarcoma; Anemia; Chronic myeloid leukemia; Tyrosine kinase inhibitor; Nilotinib; Metastasis; Case report |
| Core Tip |
Angiosarcoma is rare and carries a poor prognosis, often presenting subtly both clinically and radiologically. In some cases, it manifests only as persistent unexplained anemia, making early recognition difficult. The tumor may remain hidden, mimicking benign lesions, with symptoms masked or altered by concurrent treatments. In patients receiving tyrosine kinase inhibitors, such as for chronic myeloid leukemia, modulation of the vascular endothelial growth factor pathway and related mechanisms can further obscure tumor behavior and distort imaging findings, contributing to diagnostic delay. |
| Publish Date |
2026-04-08 07:28 |
| Citation |
Najdi T, Seif S, Khoury D, Kahwagi A, Wehbe P, Karam R, El Halabi L, Slim R, Chakhtoura G, Trak V, Eid R. Hidden intestinal angiosarcoma behind anemia during tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A case report. World J Gastrointest Oncol 2026; 18(4): 116365 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i4/116365.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i4.116365 |
